Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Valeant Pharmaceuticals International (NYSE: VRX) reported final results for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. The study in treatment naive genotype 1 infected subjects was of standard design, consisting of 48 weeks of treatment with a 24-week follow-up period. It explored three weight-based doses of taribavirin: 20 mg/kg, 25 mg/kg and 30 mg/kg vs. ribavirin 800-1400 mg/day. Throughout the 72-week trial, all doses of taribavirin demonstrated comparable efficacy (sustained virologic response (SVR)) to ribavirin with consistently lower levels of anemia. In addition, relapse rates in the 25 mg/kg and 30 mg/kg arms were comparable with the ribavirin arm; supporting the premise that higher dose weight-based taribavirin may be as effective as weight based ribavirin. Valeant plans to present the full final data at the American Association for the Study of Liver Disease (AASLD) later this year.
generic viagra online
HANYS Calls On Legislature To Pass Measure To Help Families Prevent Health Care Decision Nightmares
The Healthcare Association of New York State (HANYS) called on the State Legislature to pass much-needed legislation that will better protect the rights of incapacitated patients and spare family members from the nightmare of helplessly watching their loved one"s health care wishes go unfulfilled.
News of the day
Protect Yourself From Tick And Mosquito Bites To Prevent Illness
Summer is the peak time for people to be bitten by ticks and mosquitoes, which may carry diseases that can infect humans. The Department of Health tracks cases of these diseases and has noted a recent increase in human cases of Rocky Mountain Spotted Fever and ehrlichiosis, both of which are transmitted through tick bites. TDOH urges Tennesseans to follow commonsense precautions to protect themselves and help reduce the risk of illness.
Nutrition

The Genetic Interest Group Welcomes EU Health Ministers' Move To Tackle Rare Diseases

The Genetic Interest Group, the UK patient organisation for all those affected by genetic disorders, has welcomed the adoption yesterday by EU Health Ministers of a Council Recommendation that calls on Member States to develop and implement plans or strategies for the treatment of rare diseases. Alastair Kent, Director of the Genetic Interest Group, said: "This is an important step forward for the estimated 3.5 million people in the UK who are affected by rare disease. We are also delighted that this initiative has received wide cross-party support. It now needs to be taken forward in all the nations of the UK." He added: "It is important that families affected by rare conditions are offered a strategic approach to the provision of their healthcare. We are still hearing frequently that patients are having difficulties accessing high quality care and services. A national strategy for integrated service delivery would help to ensure that these vital services reach all the people who so desperately need them." Dr Peter Corry, a leading Paediatrician at St Luke"s Hospital, Bradford, said: "Diagnosing rare diseases, many of which are severe or life-threatening, is often difficult and the complex treatments required may involve several specialists. A national strategy that integrated rare disease services would enable patients and health professionals to provide and use best practice care and the health services to make best use of scarce expertise and improve outcomes for patients." There are over 6000 rare conditions identified, and they affect over 3.5 million people in the UK and over 30 million people in the EU at some point in their life. Notes -- The Genetic Interest Group (GIG) is a UK national alliance of organisations with a membership of over 130 charities that support children, families and individuals affected by genetic disorders. -- GIG"s primary goal is to promote awareness and understanding of genetic disorders so that high quality services for people affected by genetic conditions are developed and made available to all who need them. -- Individually, many genetic conditions are rare and as such it is difficult to raise their profile and the needs of those affected by them. GIG provides a common platform from which effective programmes to raise awareness, inform the media and influence government, industry and the NHS can be launched -- As an organisation focusing on issues of policy and practice GIG keeps an active watch on developments in the UK and Europe that will influence the effective transfer of knowledge and understanding into products and services for families that are supported by our member groups. -- In a potentially controversial field like genetics GIG provides a strong voice advocating the benefits of scientific progress in understanding the contribution being made now and that will be made in the years to come for improving health and combating many currently incurable diseases. -- For more information please go to http://www.gig.org.uk -- The Genetic Interest Group has jointly founded Rare Disease UK with others in response to unmet health care needs of families who currently struggle to get access to integrated care and support from the NHS. -- The EU"s Council of Ministers consists of representatives of Member States at ministerial level. In this case, the Member States" Health Ministers (collectively known as the Health Council) have adopted the Council Recommendation on a European action in the field of Rare Diseases. -- The Council Recommendation is important because it calls for concerted action at EU and national level in order to: - Ensure that rare diseases are adequately coded and classified - Enhance research in the field of rare diseases - Identify Centres of Expertise and foster their participation into European Reference Networks - Support the pooling of expertise at European level - Share assessments on the clinical added value of orphan drugs - Foster patient empowerment by involving patients and their representatives at all stages of the decision-making process - Ensure the sustainability of infrastructures developed for rare diseases Genetic Interest Group


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009